Colorectal cancers (CRC) are the second most leading cause of cancer deaths worldwide (2020). To aid in the early diagnosis and direct treatment trajectories for CRC patients, molecular/genetic profiling is invaluable. Our new CRC circulating tumor DNA (ctDNA) reference panel is made with a unique blend of engineered cell lines with clinically relevant mutations specific to CRCs. This panel mimics ctDNA and can be used as a reference material to validate NGS and other molecular biology workflows for the detection of key actionable mutations in genes like AKT1, APC, BRAF, KRAS, PIK3CA and TP53 (please refer table below to see full list of genes). The allelic frequencies for the variants in the panel are as low as 1.25% with a scope of diluting further using our matched Negative Control - HD843, enabling assessment of minimal residual disease (MRD) typically replicating post-surgery and post-adjuvant treatment conditions. This reference material can also be used to validate companion diagnostic (CDx) tests which are used for tailoring treatments depending on the genetic make-up of the tumors for improved prognosis. The CRC ctDNA reference panel is a blend of highly characterized, cell line derived, clinically relevant mutations manufactured under ISO 9001:2015 and ISO 13485:2016.
Genes covered: ABL1, ALK, ATK1, APC, BRAF, PIK3CA, KRAS, NRAS, PTEN, TP53
COSMICs: 10. See table below for full details
Allelic frequencies: 1.25% - 8.00%
Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0
Fragment size: 160 bp
Unit size: 350 ng per vial
Concentration: 20 ng/µl
|Gene||COSMIC ID (v97)||DNA sequence change||Amino acid change||Expected allelic frequency (%)|
Expiration: See all product shelf life information
Intended use: For assay developers, molecular diagnostic labs (Research use only)
Fragmentation size: D1000 DNA ScreenTape assay
Allelic frequency: Droplet Digital™ PCR
Quantification: Qubit® dsDNA BR assay (Invitrogen)
Certificate of analysis
The Colorectal Cancer ctDNA Panel reference standard negative control is well characterized, cell line-derived control material manufactured under ISO 9001:2015 and ISO 13485:2016 that is tested negative for 10 variants across 10 genes clinically relevant to colorectal cancers.